| 94.78 0 (0%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 114.23 | 1-year : | 133.42 |
| Resists | First : | 97.8 | Second : | 114.23 |
| Pivot price | 92.45  |
|||
| Supports | First : | 90.4 | Second : | 85.83 |
| MAs | MA(5) : | 95.13 |
MA(20) : | 91.27 |
| MA(100) : | 92.05 |
MA(250) : | 94.73 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 70.4 |
D(3) : | 77.6 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 107.73 | Low : | 84.58 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZBH ] has closed below upper band by 25.0%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 96.7 - 97.19 | 97.19 - 97.59 |
| Low: | 93.47 - 93.98 | 93.98 - 94.41 |
| Close: | 94.03 - 94.83 | 94.83 - 95.49 |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Sun, 19 Apr 2026
Zimmer Biomet stock (US98956P1021): Is its orthopedics dominance still the key to steady investor re - AD HOC NEWS
Sun, 19 Apr 2026
Is Zimmer Biomet Stock Worth Watching Right Now - Kalkine Media
Fri, 17 Apr 2026
Zimmer Biomet Receives FDA Clearance for Expanded Reverse Shoulder Systems - Orthopedics This Week
Fri, 17 Apr 2026
Leerink Sees Limited Near-Term Upside for Zimmer Biomet Holdings, Inc. (ZBH) Ahead of 2027 Catalysts - Yahoo Finance
Fri, 17 Apr 2026
Thomasville National Bank Sells 102,815 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Thu, 16 Apr 2026
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Short Interest Up 24.8% in March - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 196 (M) |
| Shares Float | 195 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 8,020 (K) |
| Shares Short P.Month | 8,410 (K) |
| EPS | 3.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 64.94 |
| Profit Margin | 8.5 % |
| Operating Margin | 13.9 % |
| Return on Assets (ttm) | 3.9 % |
| Return on Equity (ttm) | 5.5 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 29.33 |
| Sales Per Share | 42.06 |
| EBITDA (p.s.) | 12.77 |
| Qtrly Earnings Growth | -40.8 % |
| Operating Cash Flow | 1,700 (M) |
| Levered Free Cash Flow | 1,350 (M) |
| PE Ratio | 26.69 |
| PEG Ratio | 0 |
| Price to Book value | 1.45 |
| Price to Sales | 2.25 |
| Price to Cash Flow | 10.9 |
| Dividend | 0.23 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|